Ascorbic acid blocks the growth inhibitory effect of tumor necrosis factor-α on endothelial cells

Experimental Biology and Medicine

Volumn 228, Issue 7, 2003, Pages 855-865

  Saeed, Rubina W ^a   Peng, Tina ^a   Metz, Christine N ^a  

^a N Shore Long Isl Jewish Res Inst ^*  (United States)

Author keywords

Cellular activation; Cellular proliferation; Endothelial cells; Inflammation

Indexed keywords

ASCORBIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; CELL ADHESION MOLECULE; CHEMOKINE; COLLAGEN TYPE 4; VASCULOTROPIN RECEPTOR;

ARTICLE; ATHEROSCLEROSIS; CELL ACTIVATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GROWTH INHIBITION; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; VASCULAR ENDOTHELIUM; ADULT; APOPTOSIS; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; CELL NUCLEUS; COMPARATIVE STUDY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; LIPID PEROXIDATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ADULT; ANTIOXIDANTS; APOPTOSIS; ASCORBIC ACID; CELL ADHESION MOLECULES; CELL DIVISION; CELL NUCLEUS; CELLS, CULTURED; CHEMOKINES; COLLAGEN TYPE IV; ENDOTHELIUM, VASCULAR; HUMANS; LIPID PEROXIDATION; NF-KAPPA B; PHOSPHORYLATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINOBLASTOMA PROTEIN; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0141456374     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/15353702-0322807-12     Document Type: Article

References (80)

1. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527-3561, 1998.
2. Montrucchio G, Lupia E, Battaglia E, Passerini G, Bussolino F, Emanuelli G, Camussi G. Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med 180:377-382, 1994.
3. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329:630-632, 1987.
4. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 84:5277-5281, 1987.
5. Sato N, Goto T, Haranaka K, Satomi N, Nariuchi H, Mano-Hirano Y, Sawasaki Y. Actions of tumor necrosis factor on cultured vascular endothelial cells: Morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst 76:1113-1121, 1986.
6. Yilmaz A, Bieler G, Spertini O, Lejeune FJ, Ruegg C. Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon-gamma results in simultaneous synergistic and reversible effects on proliferation and morphology. Int J Cancer 77:592-599, 1998.
7. Schweigerer L, Malerstein B, Gospodarowicz D. Tumor necrosis factor inhibits the proliferation of cultured capillary endothelial cells. Biochem Biophys Res Commun 143:997-1004, 1987.
8. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4:408-414, 1998.
9. Guo DQ, Wu LW, Dunbar JD, Ozes ON, Mayo LD, Kessler KM, Gustin JA, Baerwald MR, Jaffe EA, Warren RS, Donner DB. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 275:11216-11221, 2000.
10. Lopez-Marure R, Bernal AE, Zentella A. Interference with c-myc expression and RB phosphorylation during TNF-mediated growth arrest in human endothelial cells. Biochem Biophys Res Commun 236:819-824, 1997.
11. Lopez-Marure R, Ventura JL, Sanchez L, Montano LF, Zentella A. Ceramide mimics tumour necrosis factor-alpha in the induction of cell cycle arrest in endothelial cells. Induction of the tumour suppressor p53 with decrease in retinoblastoma/protein levels. Eur J Biochem 267:4325-4333, 2000.
12. Nakagami H, Cui TX, Iwai M, Shiuchi T, Takeda-Matsubara Y, Wu L, Horiuchi M. Tumor necrosis factor-alpha inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells. Arterioscler Thromb Vasc Biol 22:238-242, 2002.
13. Bruunsgaard H, Skinhoj P, Pedersen AN, Schroll M, Pedersen BK. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol 121:255-260, 2000.
14. Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R, Bond MG, de Faire U, Nilsson J, Eriksson P, Hamsten A. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 23:376-383, 2002.
15. Lynch SM, Gaziano JM, Frei B. Ascorbic acid and atherosclerotic cardiovascular disease. Subcell Biochem 25:331-367, 1996.
16. Nakata Y, Maeda N. Vulnerable atherosclerotic plaque morphology in apolipoprotein E-deficient mice unable to make ascorbic acid. Circulation 105:1485-1490, 2002.
17. Salonen JT, Nyyssonen K, Salonen R, Lakka HM, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Lakka TA, Rissanen T, Leskinen L, Tuomainen TP, Valkonen VP, Ristonmaa U, Poulsen HE. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 248:377-386, 2000.
18. Neuzil J, Thomas SR, Stocker R. Requirement for, promotion, or inhibition by alpha-tocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation. Free Radic Biol Med 22:57-71, 1997.
19. Langlois M, Duprez D, Delanghe J, De Buyzere M, Clement DL. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 103:1863-1868, 2001.
20. Kunz J. Proliferation, migration and cell renewal within the arterial wall. Acta Histochem Suppl 27:233-243, 1983.
21. Choy JC, Granville DJ, Hunt DW, McManus BM. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 33:1673-1690, 2001.
22. Rossig LS, Dimmeler S, Zeiher AM. Apoptosis in the vascular wall and atherosclerosis. Basic Res Cardiol 96:11-22, 2001.
23. Rossig LJ, Hoffmann J, Hugel B, Mallat Z, Haase A, Freyssinet JM, Tedgui A, Aicher A, Zeiher AM, Dimmeler S. Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation 104:2182-2187, 2001.
24. Levine M, Wang Y, Padayatty SJ, Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA 98:9842-9846, 2001.
25. Relou IA, Damen CA, van der Schaft DW, Groenewegen G, Griffioen AW. Effect of culture conditions on endothelial cell growth and responsiveness. Tissue Cell 30:525-530, 1998.
26. Branch DR, Shah A, Guilbert LJ. A specific and reliable bioassay for the detection of femtomolar levels of human and murine tumor necrosis factors. J Immunol Methods 143:251-261, 1991.
27. Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, Wang D, Warren RS, Donner DB. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 275:5096-5103, 2000.
28. Wu D, Koga T, Martin KR, Meydani M. Effect of vitamin E on human aortic endothelial cell production of chemokines and adhesion to monocytes. Atherosclerosis 147:297-307, 1999.
29. Faruqi R, de la Motte C, DiCorleto PE. Alpha-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J Clin Invest 94:592-600, 1994.
30. Bowie AG, O'Neill LA. Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol 165:7180-7188, 2000.
31. Zhang WJ, Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 15:2423-2432, 2001.
32. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141-179, 1994.
33. Bowie AG, Moynagh PN, O'Neill LA. Lipid peroxidation is involved in the activation of NF-kappaB by tumor necrosis factor but not interleukin-1 in the human endothelial cell line ECV304. Lack of involvement of H2O2 in NF-kappaB activation by either cytokine in both primary and transformed endothelial cells. J Biol Chem 272:25941-25950, 1997.
34. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22, 1999.
35. Petrova TV, Makinen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res 253:117-130, 1999.
36. Patterson C, Perrella MA, Endege WO, Yoshizumi M, Lee ME, Haber E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J Clin Invest 98:490-496, 1996.
37. Giraudo E, Primo L, Audero E, Gerber HP, Koolwijk P, Soker S, Klagsbrun M, Ferrara N, Bussolino F. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 273:22128-22135, 1998.
38. Sage H, Pritzl P, Bornstein P. Endothelial cells secrete a novel collagen type in vitro independently of prolyl hydroxylation. Coll Relat Res 2:465-479, 1982.
39. Mahmoodian F, Peterkofsky B. Vitamin C deficiency in guinea pigs differentially affects the expression of type IV collagen, laminin, and elastin in blood vessels. J Nutr 129:83-91, 1999.
40. Form DM, Pratt BM, Madri JA. Endothelial cell proliferation during angiogenesis. In vitro modulation by basement membrane components. Lab Invest 55:521-530, 1986.
41. Funyu J, Mochida S, Inao M, Matsui A, Fujiwara K. VEGF can act as vascular permeability factor in the hepatic sinusoids through upregulation of porosity of endothelial cells. Biochem Biophys Res Commun 280:481-485, 2001.
42. Albuquerque ML, Waters CM, Savla U, Schnaper HW, Flozak AS. Shear stress enhances human endothelial cell wound closure in vitro. Am J Physiol Heart Circ Physiol 279:H293-H302, 2000.
43. Genersch E, Hayess K, Neuenfeld Y, Haller H. Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: Involvement of Ras-dependent and -independent pathways. J Cell Sci 113:4319-4330, 2000.
44. Kawauchi J, Zhang C, Nobori K, Hashimoto Y, T Adachi M, Noda A, Sunamori M, Kitajima S. Transcriptional repressor ATF3 protects human umbilical vein endothelial cells from TNF-alpha-induced apoptosis through down-regulation of p53 transcription. J Biol Chem 277:39025-39034, 2002.
45. Jin HM, Liu QH, Cao X, Wu ZH, Zhang GP, Zhang M, Sha ZY. Dysfunction of microvascular endothelial cells induced by tumor necrosis factor (TNFalpha): cellular and molecular mechanism. Clin Hemorheol Microcirc 23:109-112, 2000.
46. Meerarani P, Ramadass P, Toborek M, Bauer HC, Bauer H, Hennig B. Zinc protects against apoptosis of endothelial cells induced by linoleic acid and tumor necrosis factor alpha. Am J Clin Nutr 71:81-87, 2000.
47. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 88:10-15, 2001.
48. Deshpande SS, Angkeow P, Huang J, Ozaki M, Irani K. Rac1 inhibits TNF-alpha-induced endothelial cell apoptosis: dual regulation by reactive oxygen species. FASEB J 14:1705-1714, 2000.
49. Wu F, Tyml K, Wilson JX. Ascorbate inhibits iNOS expression in endotoxin- and IFN gamma-stimulated rat skeletal muscle endothelial cells. FEBS Lett 520:122-126, 2002.
50. Hediger MA. New view at C. Nat Med 8:445-446, 2002.
51. Levine M, Wang Y, Padayatty SJ, Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA 98:9842-9846, 2001.
52. Sakagami H, Satoh K, Fukuchi K, Gomi K, Takeda M. Effect on an iron-chelator on ascorbate-induced cytotoxicity. Free Radic Biol Med 23:260-270, 1997.
53. Schmidt RJ, Chung LY, Andrews AM, Turner TD. Toxicity of L-ascorbic acid to L929 fibroblast cultures: relevance to biocompatibility testing of materials for use in wound management. J Biomed Mater Res 27:521-527, 1993.
54. Hanashima C, Namiki H. Reduced viability of vascular endothelial cells by high concentration of ascorbic acid in vitreous humor. Cell Biol Int 23:287-298, 1999.
55. Harris SR, Panaro NJ, Thorgeirsson UP. Oxidative stress contributes to the anti-proliferative effects of flavone acetic acid on endothelial cells. Anticancer Res 20:2249-2254, 2000.
56. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 106:148-156, 2001.
57. Spyridopoulos I, Brogi E, Kearney M, Sullivan AB, Cetrulo C, Isner JM, Losordo DW. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: Balance between growth and death signals. J Mol Cell Cardiol 29:1321-1330, 1997.
58. Maragoudakis ME, Sarmonika M, Panoutsacopoulou M. Inhibition of basement membrane biosynthesis prevents angiogenesis. J Pharmacol Exp Ther 244:729-733, 1988.
59. McAuslan BR, Reilly W, Hannan GN, Schindhelm K, Milthorpe B, Saur BA. Induction of endothelial cell migration by proline analogs and its relevance to angiogenesis. Exp Cell Res 176:248-257, 1988.
60. Thiele J, Rompcik V, Wagner S, Fischer R. Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: An immuno-morphometric study on trephine biopsies of the bone marrow. Br J Haematol 80:227-234, 1992.
61. Mercier P, Ekindjian OG. Collagen type IV: major component of basement membranes. Current knowledge. Ann Biol Clin (Paris) 48:695-711, 1990.
62. Peterkofsky B. Ascorbate requirement for hydroxylation and secretion of procollagen: Relationship to inhibition of collagen synthesis in scurvy. Am J Clin Nutr 54:1135S-1140S, 1991.
63. Rixen H, Kirkpatrick CJ, Schmitz U, Ruchatz D, Mittermayer C. Interaction between endothelial cells and basement membrane components. In vitro studies on endothelial cell adhesion to collagen types I, III, IV and high molecular weight fragments of IV. Exp Cell Biol 57:315-323, 1989.
64. Meredith JE Jr, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 4:953-961, 1993.
65. Shekhonin BV, Domogatsky SP, Idelson GL, Koteliansky VE, Rukosuev VS. Relative distribution of fibronectin and type I, III, IV, V collagens in normal and atherosclerotic intima of human arteries. Atherosclerosis 67:9-16, 1987.
66. Mackay AR, Ballin M, Pelina MD, Farina AR, Nason AM, Hartzler JL, Thorgeirsson UP. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 12:168-184, 1992.
67. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh W. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J 296:803-809, 1993.
68. Yao J, Bone RC, Sawhney RS. Differential effects of tumor necrosis factor-alpha on the expression of fibronectin and collagen genes in cultured bovine endothelial cells. Cell Mol Biol Res 41:17-28, 1995.
69. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151-160, 1997.
70. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: Emerging paradigms of signal transduction. Annu Rev Cell Dev Biol 11:549-599, 1995.
71. Buckley S, Driscoll B, Anderson KD, Warburton D. Cell cycle in alveolar epithelial type II cells: Integration of Matrigel and KGF. Am J Physiol 273:L572-L580, 1997.
72. Roy J, Tran PK, Religa P, Kazi M, Henderson B, Lundmark K, Hedin U. Fibronectin promotes cell cycle entry in smooth muscle cells in primary culture. Exp Cell Res 273:169-177, 2002.
73. Takahashi K, Suzuki K, Uehara Y, Ono T. Growth inhibition by anchorage-deficiency is associated with increased level but reduced phosphorylation of mutant p53. Japan J Cancer Res 83:358-365, 1992.
74. Wu RC, Schonthal AH. Activation of p53-p21waf1 pathway in response to disruption of cell-matrix interactions. J Biol Chem 272:29091-29098, 1997.
75. Lassus P, Roux P, Zugasti O, Philips A, Fort P, Hibner U. Extinction of rac1 and Cdc42Hs signalling defines a novel p53-dependent apoptotic pathway. Oncogene 19:2377-2385, 2000.
76. Pohlman TH, Harlan JM. Human endothelial cell response to lipopolysaccharide, interleukin-1, and tumor necrosis factor is regulated by protein synthesis. Cell Immunol 119:41-52, 1989.
77. Karsan A, Yee E, Harlan JM. Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, A1. J Biol Chem 271:27201-27204, 1996.
78. Slowik MR, Min W, Ardito T, Karsan A, Kashgarian M, Pober JS. Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by interleukin-1-converting enzyme-like protease-dependent and -independent pathways. Lab Invest 77:257-267, 1997.
79. Polunovsky VA, Wendt CH, Ingbar DH, Peterson MS, Bitterman PB. Induction of endothelial cell apoptosis by TNF alpha: modulation by inhibitors of protein synthesis. Exp Cell Res 214:584-594, 1994.
80. Emmanuel C, Foo E, Medbury HJ, Matthews J, Comis A, Zoellner H. Synergistic induction of apoptosis in human endothelial cells by tumour necrosis factor-alpha and transforming growth factor-beta. Cytokine 18:237-241, 2002.